Clinical Trial Update: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]

View source ↗

Summary

This is an update on a Phase 1 trial of interleukin-15 armored GPC3-specific CAR-T cells for pediatric solid tumors, with results posted and the study currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatoblastoma
• Liposarcoma
• Malignant Rhabdoid Tumor
• Rhabdomyosarcoma
• Wilms Tumor
• Yolk Sac Tumor

Drugs mentioned

• GPC3-targeted IL-15 armored CAR-T cells (GPC3-targeted IL-15 armored CAR-T cells)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Liver Cancer, Rhabdomyosarcoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-21